NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ADVM Stock Alerts $9.39 -0.80 (-7.85%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$9.34▼$10.2250-Day Range$10.19▼$21.0052-Week Range$7.10▼$29.70Volume847,544 shsAverage Volume249,470 shsMarket Capitalization$194.84 millionP/E RatioN/ADividend YieldN/APrice Target$34.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Adverum Biotechnologies alerts: Email Address Adverum Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside269.2% Upside$34.67 Price TargetShort InterestBearish7.54% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.32Based on 3 Articles This WeekInsider TradingAcquiring Shares$135,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($5.18) to ($5.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.79 out of 5 starsMedical Sector163rd out of 907 stocksBiological Products, Except Diagnostic Industry18th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.54% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Adverum Biotechnologies has recently increased by 26.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Adverum Biotechnologies is -0.78. Previous Next 2.4 News and Social Media Coverage News SentimentAdverum Biotechnologies has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adverum Biotechnologies this week, compared to 1 article on an average week.Search Interest7 people have searched for ADVM on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($5.18) to ($5.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Adverum Biotechnologies Stock (NASDAQ:ADVM)Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More ADVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADVM Stock News HeadlinesApril 25, 2024 | globenewswire.comAdverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingApril 20, 2024 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Shares Pass Below 200 Day Moving Average of $12.09April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 18, 2024 | money.usnews.comAdverum Biotechnologies IncMarch 28, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)March 21, 2024 | markets.businessinsider.comPositive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial PositionMarch 20, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial AdjustmentsMarch 19, 2024 | finance.yahoo.comIs Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 19, 2024 | markets.businessinsider.comAdverum Biotechnologies (ADVM) Receives a Buy from TD CowenMarch 18, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023March 18, 2024 | globenewswire.comAdverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesMarch 17, 2024 | seekingalpha.comADVM Adverum Biotechnologies, Inc.March 6, 2024 | finance.yahoo.comADVM Apr 2024 5.000 callMarch 6, 2024 | investorplace.comTurn Pocket Change into Profit: 3 Penny Stocks Ready to PopFebruary 28, 2024 | globenewswire.comAdverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsFebruary 25, 2024 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 10.53% to 4.28February 22, 2024 | benzinga.comAdverum Biotechnologies Stock (NASDAQ:ADVM), Short Interest ReportFebruary 22, 2024 | investorplace.comUnleash Massive Returns With These 3 Top Penny StocksFebruary 15, 2024 | finance.yahoo.comADVM Feb 2024 4.000 callFebruary 13, 2024 | finance.yahoo.comADVM Sep 2024 2.500 putFebruary 12, 2024 | finance.yahoo.comAdverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 9, 2024 | uk.investing.comAdverum Biotechnologies Inc (ADVM)February 8, 2024 | msn.comWhy Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?February 8, 2024 | finance.yahoo.comAdverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDFebruary 7, 2024 | msn.comAdverum Biotechnologies Awaits Court Decision on SettlementSee More Headlines Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADVM CUSIPN/A CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees121Year FoundedN/APrice Target and Rating Average Stock Price Target$34.67 High Stock Price Target$60.00 Low Stock Price Target$4.00 Potential Upside/Downside+269.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($11.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,170,000.00 Net MarginsN/A Pretax Margin-3,284.53% Return on Equity-98.65% Return on Assets-52.85% Debt Debt-to-Equity RatioN/A Current Ratio4.13 Quick Ratio4.13 Sales & Book Value Annual Sales$3.60 million Price / Sales54.12 Cash FlowN/A Price / Cash FlowN/A Book Value$8.26 per share Price / Book1.14Miscellaneous Outstanding Shares20,750,000Free Float19,655,000Market Cap$194.84 million OptionableOptionable Beta0.84 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Laurent Fischer (Age 60)President, CEO & Director Comp: $1.02MMs. Linda M. Rubinstein M.A. (Age 57)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $940.99kMr. Kishor Peter Soparkar J.D. (Age 52)Chief Operating Officer Comp: $674.98kDr. Setareh Seyedkazemi Pharm.D. (Age 49)Chief Development Officer Comp: $656.84kDr. R. Andrew Ramelmeier Ph.D. (Age 62)Chief Technology Officer Dr. Romuald Corbau Ph.D. (Age 55)Chief Scientific Officer Mr. John W. Rakow J.D. (Age 67)Senior VP & General Counsel Comp: $954.24kMs. Dena HouseChief People OfficerMs. Carla FiankanSenior Vice President of Regulatory AffairsMr. Michael SteelSenior Vice President of QualityMore ExecutivesKey CompetitorsSutro BiopharmaNASDAQ:STROElevation OncologyNASDAQ:ELEVCompass TherapeuticsNASDAQ:CMPXCoherus BioSciencesNASDAQ:CHRSPoseida TherapeuticsNASDAQ:PSTXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 358,719 shares on 4/24/2024Ownership: 1.729%BML Capital Management LLCSold 3,721,135 shares on 4/23/2024Ownership: 4.014%Vivo Capital LLCBought 1,500,000 shares on 4/22/2024Ownership: 7.229%Twin Focus Capital Partners LLCBought 100,000 shares on 3/5/2024Ownership: 0.099%AIGH Capital Management LLCBought 1,848,834 shares on 2/12/2024Ownership: 3.140%View All Insider TransactionsView All Institutional Transactions ADVM Stock Analysis - Frequently Asked Questions Should I buy or sell Adverum Biotechnologies stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADVM shares. View ADVM analyst ratings or view top-rated stocks. What is Adverum Biotechnologies' stock price target for 2024? 3 Wall Street research analysts have issued 1-year target prices for Adverum Biotechnologies' stock. Their ADVM share price targets range from $4.00 to $60.00. On average, they expect the company's share price to reach $34.67 in the next twelve months. This suggests a possible upside of 269.2% from the stock's current price. View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts. How have ADVM shares performed in 2024? Adverum Biotechnologies' stock was trading at $7.5280 at the start of the year. Since then, ADVM stock has increased by 24.7% and is now trading at $9.39. View the best growth stocks for 2024 here. Are investors shorting Adverum Biotechnologies? Adverum Biotechnologies saw a increase in short interest in April. As of April 15th, there was short interest totaling 1,130,000 shares, an increase of 27.0% from the March 31st total of 890,000 shares. Based on an average daily volume of 276,500 shares, the days-to-cover ratio is presently 4.1 days. Currently, 7.5% of the company's stock are short sold. View Adverum Biotechnologies' Short Interest. When is Adverum Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ADVM earnings forecast. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) issued its earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) EPS for the quarter, topping analysts' consensus estimates of ($2.80) by $0.50. When did Adverum Biotechnologies' stock split? Adverum Biotechnologies's stock reverse split on Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO? 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA). Who are Adverum Biotechnologies' major shareholders? Adverum Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include Vivo Capital LLC (7.23%), BML Capital Management LLC (4.01%) and Assenagon Asset Management S.A. (1.73%). Insiders that own company stock include Brigit Riley, Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi. View institutional ownership trends. How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADVM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
